When Antidepressants Don’t Work: Next Steps for TRD

If you have tried two or more antidepressants at adequate doses for a sufficient duration and still do not feel like yourself, you are not a treatment failure. Treatment-resistant depression is a recognized clinical diagnosis — and it comes with a structured set of next steps that go well beyond simply trying another medication. Understanding what those options are, and why they exist, is often the clearest first move toward finding an approach that actually works for your biology and your life.

This guide walks through what treatment-resistant depression actually means clinically, why standard antidepressants fall short for some patients, and what evidence-based options are available when the standard approach has not delivered results.

Quick Summary

• Treatment-resistant depression (TRD) is formally defined as a failure to respond to at least two antidepressant trials at adequate doses and duration.
• The reasons antidepressants may not work are biological, pharmacological, and diagnostic — not personal.
• Advanced TRD treatment options include augmentation strategies, medication switches, ketamine-based therapies, neuromodulation, and psychotherapy combinations.
• Clinicians approach TRD systematically, not through random trial-and-error.
• Knowing the right questions to ask your psychiatric provider can meaningfully change the direction of your care.

What Qualifies as Treatment-Resistant Depression

The term treatment-resistant depression has a specific clinical meaning. According to the Mayo Clinic, TRD is generally defined as depression that has not responded adequately to at least two different antidepressant treatments, each tried at an appropriate dose for an appropriate length of time — typically six to eight weeks at a therapeutic dose.

This distinction matters because it separates two very different clinical situations:

• Undertreated depression — where the medication dose was too low, the trial period was too short, or the medication was discontinued before it had time to work.
• Treatment-resistant depression — where the medication was given a genuine, adequate trial and the response was still insufficient.

TRD is not rare. The National Institute of Mental Health recognizes that a meaningful portion of people diagnosed with major depressive disorder do not achieve full remission with first-line treatments. If you have been through multiple medication trials with partial response or no response, the clinical picture changes — and so should the treatment approach.

It is also worth noting that a diagnosis of TRD sometimes prompts a re-evaluation of the original diagnosis. Conditions like bipolar disorder, ADHD, hypothyroidism, chronic sleep disorders, and anxiety disorders can present similarly to or co-occur with depression — and when unaddressed, they can make antidepressants appear ineffective when the underlying issue is actually diagnostic, not pharmacological.

Why Standard Antidepressants Fall Short for Some Patients

Antidepressants are not a single category of medication. SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants each work through different mechanisms. But even across these options, the common thread is that most standard antidepressants target monoamine neurotransmitters — primarily serotonin, norepinephrine, and dopamine.

For some patients, that mechanism simply does not address what is driving their depression. Several factors can explain this:

Genetic and Metabolic Differences

Pharmacogenomic variation affects how individuals metabolize psychiatric medications. Some people are rapid metabolizers, meaning a standard dose clears their system too quickly to reach therapeutic blood levels. Others are poor metabolizers, meaning they accumulate the medication in ways that produce side effects before achieving clinical benefit. Pharmacogenomic testing — which assesses how your specific genetic profile processes medications — can sometimes clarify why a medication that works for others has not worked for you.

Inflammatory and Neuroimmune Factors

Emerging research suggests that for a subset of patients, depression is driven in part by inflammatory processes that standard antidepressants do not directly address. This is an active area of research, but it is part of why the field has moved toward recognizing that depression is not a single disease with a single mechanism.

Untreated Comorbidities

Chronic anxiety, trauma history, substance use, and medical conditions can all blunt antidepressant response. When these go unaddressed, the depression itself may remain partially or fully treatment-resistant regardless of which medication is used.

Inadequate Prior Trials

Sometimes what appears to be treatment resistance is actually a series of inadequate trials — doses that were too conservative, durations that were too short, or discontinuations driven by manageable side effects before the medication had time to work. A thorough psychiatric medication management review can sometimes reveal this pattern.

Evidence-Based Advanced Treatment Options for TRD

When two or more adequate antidepressant trials have not produced sufficient results, clinical guidelines support moving to a more advanced treatment tier. These are not experimental options — they are evidence-based strategies developed specifically for this clinical situation.

Augmentation Strategies

Augmentation means adding a second medication to an existing antidepressant to enhance its effect. Common augmentation strategies include:

• Lithium augmentation — one of the longest-studied augmentation approaches in psychiatry, particularly for patients with more severe or recurrent depression.
• Atypical antipsychotic augmentation — medications such as aripiprazole, quetiapine, or brexpiprazole have FDA approval as adjunctive treatments for depression when antidepressants alone are insufficient.
• Thyroid hormone augmentation — sometimes used when thyroid function, even in the low-normal range, may be contributing to antidepressant non-response.
• Buspirone or bupropion addition — these are often considered when targeting specific symptom clusters such as anxiety, low energy, or cognitive fog.

Augmentation decisions are not arbitrary. Each choice is guided by a patient’s symptom profile, side effect history, and what partial response, if any, the current antidepressant has produced.

Medication Class Switch

If augmentation is not appropriate or has already been tried, switching to a medication class with a different mechanism of action is a logical next step. Moving from an SSRI to an SNRI, a TCA, or a MAOI represents a meaningful mechanistic shift — not just changing brands within the same category.

Ketamine and Esketamine

This is one of the most significant advances in TRD treatment in recent decades. Ketamine and its derivative esketamine work through the glutamate system — a fundamentally different mechanism than traditional antidepressants — and can produce antidepressant effects within hours to days rather than weeks.

In 2019, the FDA approved esketamine (Spravato) as a nasal spray specifically for treatment-resistant depression. You can read the FDA’s announcement on esketamine approval for details on the indication and administration requirements. Research published through PubMed Central on ketamine’s rapid antidepressant effects supports its use particularly in patients who have not responded to standard treatments and in cases involving acute suicidal ideation.

Ketamine-based treatment is not appropriate for every patient. It requires careful clinical screening and is administered in certified settings. But for qualifying patients, it represents a meaningfully different pathway when monoamine-based approaches have fallen short.

Neuromodulation Therapies

Transcranial magnetic stimulation (TMS) is an FDA-cleared, non-invasive procedure that uses magnetic pulses to stimulate specific regions of the brain associated with mood regulation. TMS is typically recommended when medication trials have been inadequate. It does not require anesthesia, has a favorable side effect profile, and is often covered by insurance for patients who meet TRD criteria.

Electroconvulsive therapy (ECT) remains one of the most effective treatments available for severe, treatment-resistant depression, particularly in cases involving psychotic features, severe suicidality, or complete non-response to other treatments. Despite its historical stigma, modern ECT is administered under anesthesia and has a well-established evidence base.

Structured Psychotherapy as Part of Treatment

Medication alone is rarely the complete answer in TRD. Evidence-based psychotherapy approaches — particularly cognitive behavioral therapy (CBT) and behavioral activation — add meaningful benefit when combined with pharmacological treatment. For patients with significant trauma histories, trauma-focused approaches such as EMDR may also be relevant.

The American Psychiatric Association’s guidelines on depression treatment consistently support combined medication and psychotherapy approaches for complex or treatment-resistant presentations.

How Clinicians Approach TRD Systematically

A structured approach to TRD is not simply trying different medications in sequence and hoping something eventually works. It involves a deliberate, staged process that begins with a comprehensive reassessment.

Step 1: Verify the Diagnosis and Rule Out Contributing Factors

Before escalating treatment, a thorough psychiatric evaluation should confirm that major depressive disorder is the primary diagnosis, that no contributing medical conditions are unaddressed, and that any comorbid psychiatric conditions — anxiety disorders, ADHD, substance use, trauma — have been identified and incorporated into the treatment plan. A thorough psychiatric evaluation is foundational to getting this step right.

Step 2: Review All Prior Treatment Trials

A systematic review of prior medication trials — including doses, durations, tolerability, and degree of response — allows the clinician to distinguish true treatment resistance from inadequate prior trials. This review also identifies patterns: Did partial responses occur with certain medication classes? Were trials abandoned due to side effects before reaching therapeutic doses?

Step 3: Select a Next-Step Strategy Based on Evidence and Patient Profile

The next treatment decision is guided by the evidence base for TRD, the patient’s specific symptom profile, comorbidities, medication tolerability history, and personal preferences. This is not a one-size-fits-all algorithm. It is a clinical reasoning process that accounts for the individual in front of the provider.

Step 4: Monitor and Adjust with Structure

Once a next-step treatment is initiated, regular structured follow-up — not vague check-ins — is essential. Response should be tracked using validated symptom measures, and adjustments should be made deliberately based on clinical data, not intuition alone.

What to Expect When Escalating Your Treatment Plan

Moving into advanced TRD treatment can feel uncertain, especially after previous treatment attempts that did not deliver the results you hoped for. A few realities are worth naming directly.

• Timelines vary. Some interventions, like ketamine, can produce rapid changes. Others, like TMS or medication adjustments, require weeks before the full effect is assessable. Your provider should set clear expectations for each step.
• Side effects remain part of the equation. Advanced treatments have their own tolerability profiles. These should be discussed honestly before initiating any new approach — not minimized or glossed over.
• Partial responses are clinically meaningful. TRD treatment rarely produces an overnight transformation. Incremental improvements in sleep, energy, concentration, and daily functioning are real indicators of progress, even when full remission takes longer.
• Your input matters. A structured TRD treatment plan is not something done to you — it is developed with you. Your observations about what has helped, what has not, and what matters most for your functioning are clinically relevant data.

Whether you are accessing care in Southern California or through telehealth, working with a provider who understands TRD systematically — rather than reactively — makes a meaningful difference. Patients in the Long Beach area, for example, can access this level of structured psychiatric care through a Telehealth Psychiatric Provider in Long Beach, California, without needing to leave their home or workplace.

How to Talk to Your Psychiatric Provider About TRD

One of the most practical things you can do if you suspect you meet criteria for treatment-resistant depression is to come to your next appointment prepared. Providers who take TRD seriously will want this information — and having it organized makes the conversation more productive.

What to Bring or Be Ready to Discuss

• A list of every antidepressant you have tried, including the dose reached, how long you took it, why it was stopped, and whether you noticed any improvement.
• Any other psychiatric medications used, including augmentation agents or sleep aids.
• Your current symptom picture — what has improved, what has not, and what areas of daily functioning are still affected.
• Any significant life stressors, medical diagnoses, or sleep issues that have been present during treatment.

Questions Worth Asking

• Do my prior trials qualify me for a TRD diagnosis, or is there reason to believe earlier trials were inadequate?
• Should we consider pharmacogenomic testing before trying another medication?
• Am I a candidate for augmentation, or does it make more clinical sense to switch medication classes entirely?
• What are the criteria for considering ketamine or TMS at this stage of my treatment?
• How will we measure whether the next step is working, and what is the plan if it does not?

These are not aggressive questions. They are the kind of questions a well-informed patient should feel comfortable asking — and that a skilled psychiatric provider should expect and welcome. If you are not sure where to start, reviewing the FAQ on telehealth psychiatry can help you understand what a structured clinical relationship looks like before your first appointment.

For patients in the Inland Empire region, structured TRD-informed care is also available through a Telehealth Psychiatric Provider in Corona, California.

The Takeaway: TRD Has a Path Forward

Treatment-resistant depression is not the end of the road. It is a specific clinical situation that calls for a more deliberate, structured approach — one that goes beyond simply rotating through standard antidepressants and applies the full range of evidence-based options available in modern psychiatry.

If your previous care has felt like guesswork — medications changed without clear reasoning, appointments that ended before your questions were answered, a treatment plan that never quite made sense — that is not what structured psychiatric medication management looks like. It is what happens when care is not tailored to the complexity of your situation.

Understanding your options is the first step. The next is working with a provider who approaches your history with clinical rigor and genuine attention to what actually matters: your ability to function, to work, to be present, and to feel like yourself again.

To learn more about how evidence-based psychiatric care is structured at D&Y Integrated Psychiatry, meet the team and see what a genuinely different clinical experience looks like — or book an appointment to begin a structured evaluation today.

Frequently Asked Questions About Treatment-Resistant Depression

How many antidepressants do I need to try before I qualify as treatment-resistant?

The standard clinical threshold is failure to achieve adequate response after two or more antidepressant trials at therapeutic doses for a sufficient duration — generally six to eight weeks per trial. However, the quality of those prior trials matters. Your psychiatric provider should review what was tried, at what doses, and for how long before confirming a TRD diagnosis.

Is ketamine the same as esketamine (Spravato)?

They are related but not identical. Esketamine (Spravato) is a nasal spray derived from ketamine that received FDA approval specifically for treatment-resistant depression in 2019. IV ketamine infusions are used off-label in clinical settings. Both target the glutamate system and can produce rapid antidepressant effects, but they differ in administration, setting, and insurance coverage.

Can TRD be treated through telehealth?

Many components of TRD care — psychiatric evaluation, medication management, augmentation strategy, and follow-up monitoring — can be managed effectively through telehealth. Interventions like TMS and ketamine infusions require in-person visits, but the coordination and psychiatric oversight surrounding these treatments can often be provided remotely by a qualified psychiatric provider.

Does having TRD mean my depression will never improve?

No. Treatment resistance describes a response pattern to a specific set of treatments — not a permanent prognosis. Many patients with TRD achieve significant symptom reduction and functional improvement when a more structured, comprehensive approach is applied. The goal of TRD-informed care is exactly that: finding the approach that works for your specific clinical picture.